Synonyms: PF-00547659 | PF-547659 | SHP647
Compound class:
Antibody
Comment: Ontamalimab (PF-00547659) is a fully human, IgG2, investigational monoclonal antibody targeting mucosal addressin cell adhesion molecule 1 (MADCAM1) [1-2]. It is being evaluated for clinical potential in inflammatory bowel diseases. PF-00547659 was granted FDA orphan drug designation for ulcerative colitis in November 2017.
|
References |
1. Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S. (2009)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol, 157 (2): 281-93. [PMID:19366349] |
2. Pullen N, Molloy E, Kellermann S-A, Green LL, Haak-Fredescho M. (2005)
Antibidies to MAdCAM. Patent number: WO2005067620. Assignee: Pfizer Inc., Amgen Fremont Inc., Pfizer Limited. Priority date: 09/01/2004. Publication date: 27/07/2005. |
3. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA et al.. (2017)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, 390 (10090): 135-144. [PMID:28527704] |
4. Wang M, Kussrow AK, Ocana MF, Chabot JR, Lepsy CS, Bornhop DJ, O'Hara DM. (2017)
Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation. Br J Pharmacol, 174 (1): 70-81. [PMID:27760281] |